激素受体阳性乳腺癌新辅助治疗的最新研究进展

李 星月1, 黄 闪闪1, 沈国 双*2
1、青海大学研究生院
2、青海大学附属医院乳腺疾病诊疗中心

摘要


乳腺癌已超过肺癌成为“全球第一大癌”。其分子分型中激素受体阳性（HR+）亚型占比超过70%，构成乳腺癌治疗领域的核心挑战。由于该亚型肿瘤异质性显著且易产生治疗抵抗，如何优化其新辅助治疗方案已成为改善患者预后的关键问题。新辅助治疗通过降低肿瘤分期、提高手术可行性及评估药物敏感性，在HR+乳腺癌综合管理中占据重要地位。本综述聚焦于激素受体阳性乳腺癌新辅助治疗的最新研究进展，详细阐述了多种治疗策略，包括内分泌治疗联合靶向药物（如CDK4/6抑制剂、PI3K抑制剂等）的应用及其疗效评估，以及化疗联合内分泌治疗的优化方案探索。通过总结这些最新研究成果，旨在为临床医生制定更为精准有效的激素受体阳性乳腺癌新辅助治疗方案提供全面而有力的参考依据，以改善患者的预后和生活质量，推动该领域临床实践的发展。为建立更精准的治疗体系提供理论依据。

关键词


激素受体阳性乳腺癌；新辅助治疗；内分泌治疗；CDK4/6抑制剂

全文:

PDF


参考


[1]Kristofovicova H, Cifuentes C, Carvajal C, et al. Neoadjuvant Radiation Therapy in the Treatment of Breast Cancer[J]. International Journal of Radiation Oncology, Biology, Physics, 2023, 117(2): e188-e189.

[2]Yu Y, Wu S, Xing H, et al. Development and Validation of a Novel Model for Predicting Prognosis of Non-PCR Patients After Neoadjuvant Therapy for Breast Cancer[J]. Frontiers in Oncology, 2021, 11: 675533.

[3]Li F, Yang Y, Wei Y, et al. Predicting neoadjuvant chemotherapy benefit using deep learning from stromal histology in breast cancer[J]. NPJ breast cancer, 2022, 8(1): 124.

[4]Mermut O, Inanc B, Gursu R U, et al. Factors affecting pathological complete response after neoadjuvant chemotherapy in breast cancer: a single-center experience[J]. Revista Da Associacao Medica Brasileira (1992), 2021, 67(6): 845-850.

[5]Zhao S, Gu J, Tian Y, et al. Low levels of sex hormone-binding globulin predict an increased breast cancer risk and its underlying molecular mechanisms[J]. Open Life Sciences, 2024, 19(1): 20220822.

[6]Egeland N G, Jonsdottir K, Lauridsen K L, et al. Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients[J]. Clinical Epidemiology, 2020, 12: 771-781.

[7]王朝斌，王殊.激素受体阳性、HER-2阳性乳腺癌新辅助治疗选择[J].中国实用外科杂志，2021，41（11）：12481252.

[8]Kearney M R, McGuinness J E, Kalinsky K. Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer[J]. Breast Cancer Research and Treatment, 2021, 189(1): 1-13.

[9]Ali M M, Mahmood N M A. The Use of Cyclin-Dependent Tyrosine Kinase 4/6 (CDK4/6) Inhibitors in Breast Cancer[J]. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ), 2022, 3: 30-35.

[10]Jabbal I S, Saravia D, Yaghi M, et al. Abstract P2-12-12: The effect of Neoadjuvant Chemotherapy in reducing the need for axillary lymph node dissection in HR+/HER2- node positive breast cancers[J]. Cancer Research, 2022, 82(4_Supplement): P2-12-12.

[11]Tamirisa N, Lin H, Shen Y, et al. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer[J]. JAMA oncology, 2020, 6(10): 1548-1554.

[12]Samuel Eziokwu A, Varella L, Lynn Kruse M, et al. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer[J]. Clinical Breast Cancer, 2021, 21(3): 205-209.

[13]Yilmaz C, Cavdar D K. Molecular biomarker discordances of breast cancer before and after neoadjuvant chemotherapy: Are they related to neoadjuvant chemotherapy or intratumoral heterogeneity and is there any clinical significance?[M]. Research Square, 2022.

[14]Berton Giachetti P P M, Morganti S, Gandini S, et al. Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer[J]. JAMA Network Open, 2025, 8(2): e2461067.

[15]Costa G P O, Ferreira-Filho E S, Simoes R D S, et al. Impact of hormone therapy on the bone density of women with premature ovarian insufficiency: A systematic review[J]. Maturitas, 2023, 167: 105-112.

[16]Brown S R, Vomhof-DeKrey E E. Current Immunotherapy Treatments of Primary Breast Cancer Subtypes[J]. Biomedicines, 2024, 12(4): 895.

[17]Lüftner D. New treatment options for hormone receptor positive breast cancer in 2023[J]. Current Opinion in Obstetrics & Gynecology, 2023, 35(1): 62-66.

[18]Cook M M, Al Rabadi L, Kaempf A J, et al. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy[J]. The Oncologist, 2021, 26(2): 101-106.

[19]Zhai J, Wu Y, Ma F, et al. Advances in medical treatment of breast cancer in 2022[J]. Cancer Innovation, 2023, 2(1): 1-17.

[20]Kumar Das D. Predicting Response to Endocrine Therapy in ER-Positive Breast Cancer[J]. Oncology Times, 2021, 43(11): 23.

[21]Santacana-Font G, Kedra D, Del Carmen García-Macías M, et al. Abstract 7576: Exemestane and its primary metabolite 17-hydroexemestane inhibit synergically the tumor growth of ER/AR positive breast cancer tumors[J]. Cancer Research, 2024, 84(6_Supplement): 7576.

[22]Gautam N, Kaur S, Kashyap S. EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C>G: A Novel Prognostic and Risk Predictive Biomarker[J]. Archives of Medical Research, 2023, 54(5): 102852.

[23]Wang T, Wang J, Zhao W, et al. Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy[J]. Clinical Breast Cancer, 2024, 24(5): e370-e378.e1.

[24]HOGSTROM J, Cruz K, Patel J, et al. Abstract 3462: Modeling drug resistance in hormone receptor positive breast cancer using patient derived organoid cultures and cancer associated fibroblasts[J]. Cancer Research, 2022, 82(12_Supplement): 3462.

[25]Hu W, Wang L, Luo J, et al. The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models[J]. Breast Cancer: Targets and Therapy, 2023, 15: 899-912.

[26]Meegdes M, Van Der Velde M G A M, Geurts S M E, et al. Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors[J]. Journal of Chemotherapy (Florence, Italy), 2024, 36(4): 343-350.

[27]Schettini F, Seguí E, Conte B, et al. Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report[J]. Frontiers in Oncology, 2022, 12: 1009352.

[28]Hurvitz S A, André F, Cristofanilli M, et al. Abstract CT063: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)[J].

[29]Zhao X, Yang X, Fu L, et al. Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients[J]. Cancer Management and Research, 2021, 13: 4579-4586.

[30]Huang R, Wu W, Guo Y, et al. Development of a model for predicting mortality of breast cancer admitted to Intensive Care Unit[J]. African Health Sciences, 2022, 22(3): 155-165.

[31]Nardin S, Ruelle T, Giannubilo I, et al. Adjuvant treatment in hormone receptor-positive early breast cancer: New approaches of endocrine therapy[J]. Tumori, 2024, 110(3): 162-167.

[32]Schipper R J, De Bruijn A, Voogd A C, et al. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients[J]. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, 47(8): 1928-1933.

[33]Zhou Z, Song X, Chi J J, et al. Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance[J]. Cellular Signalling, 2020, 70: 109574.

[34]Da Silva L R, De Andrade C A, Brenelli F, et al. Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer[J]. Breast Cancer Research and Treatment, 2021, 186(3): 753-760.

[35]Fukui R, Watanabe T, Morimoto K, et al. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers[J]. Breast Cancer (Tokyo, Japan), 2023, 30(5): 703-713.

[36]Li Z Y, Dong Y L, Cao X Z, et al. Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2023, 50(4): 74.

[37]Kim H J, Noh W C, Lee E S, et al. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer[J]. Breast cancer research: BCR, 2020, 22(1): 54.

[38]Masurkar P P, Damgacioglu H, Deshmukh A, et al. Abstract 891: Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United States[J]. Cancer Research, 2021, 81(13_Supplement): 891.

[39]Lai J I, Zhuang Y J, Lin T Y, et al. Abstract P4-01-10: A kinase inhibitor library screen reveals novel candidates that reverse CDK4/6 inhibitor resistance in CDK6 amplified HR(+) breast cancer[J]. Cancer Research, 2022, 82(4_Supplement): P4-01-10.

[40]Howard F M, Villamar D, He G, et al. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer[J]. Expert Opinion on Investigational Drugs, 2022, 31(6): 531-548.

[41]Liao H, Zhong J, Pei W, et al. Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.[J]. Journal of Clinical Oncology, 2022, 40(16_suppl): 535-535.

[42]Løkkegaard S, Elias D, Alves C L, et al. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit[J]. NPJ breast cancer, 2021, 7(1): 2.

[43]Zhou Y, Zhou J, Shi H, et al. Abstract P5-02-12: Prognostic relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy[J]. Cancer Research, 2023, 83(5_Supplement): P5-02-12.

[44]Caltabiano R, Broggi G, Tinnirello G, et al. Immune Microenvironment and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective[M]. Preprints, 2023.


Refbacks

  • 当前没有refback。